A lower allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer

Cancer Investigation

Volumn 28, Issue 9, 2010, Pages 978-982

  Tang, Ping ^a   Wang, Jianmin ^b   Hicks, David G ^a   Wang, Xi ^a   Schiffhauer, Linda ^a   McMahon, Loralee ^a   Yang, Qi ^a   Shayne, Michelle ^a   Huston, Alissa ^a   Skinner, Kristin A ^a   Griggs, Jennifer ^c   Lyman, Gary ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

21 gene assay; Breast cancer; ER; HER2; PR

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

21 GENE ASSAY; ADULT; AGE DISTRIBUTION; ALLRED SCORE; ARTICLE; BIOASSAY; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; RECURRENCE RISK; SCORING SYSTEM; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77958003355     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.496754     Document Type: Article

References (39)

1. Soerjomataram, I.; Louwman, M. W.; Ribot, J. G.; Roukema, J. A.; Coebergh, J. W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107, 309-330.
2. Ravdin, P. M.; Siminoff, L. A.; Davis, G. J.; Mercer, M. B.; Hewlett, J.; Gerson, N.; Parker, H. L. Computor program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19, 980-991.
3. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F. L.; Walker, M. G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E. R.; Wickerham, D. L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 2004, 351, 2817-2826.
4. NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology 2006, 20, 789-790.
5. Goldstein, L. J.; Gray, R.; Badve, S.; Childs, B. H.; Yoshizawa, C.; Rowley, S.; Shak, S.; Baehner, F. L.; Ravdin, P. M.; Davidson, N. E.; Sledge, G. W. Jr.; Perez, E. A.; Shulman, L. N.; Martino, S.; Sparano, J. A. Prognostic utility of the 21-gene assay in hormone receptorpositive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008, 26, 4063-4071.
6. Perou, C. M.; Sorlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A. L.; Brown, P. O.; Botstein, D. Molecular portrait of human breast tumours. Nature 2000, 406, 747-752.
7. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98, 10869-10874.
8. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100, 8418-T8423.
9. Jacquemier, J.; Ginestier, C.; Rougemont, J.; Bardou, V. J.; Charafe-Jauffret, E.; Geneix, J.; Adélaïde, J.; Koki, A.; Houvenaeghel, G.; Hassoun, J.; Maraninchi, D.; Viens, P.; Birnbaum, D.; Bertucci, F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005, 65, 767-779. (Pubitemid 40216434)
10. Abd El-Rehim, D. M.; Ball G.; Pinder, S. E.; Rakha, E.; Paish, C.; Robertson, J. F.; Macmillan, D.; Blamey, R. W.; Ellis, I. O. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116, 340-350.
11. Nielsen, T. O.; Hsu, F. D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L. A.; Ragaz, J.; Gown, A. M.; Gilks, C. B.; van de Rijn, M.; Perou, C. M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10, 5367-5374.
12. Livasy, C. A.; Karaca, G.; Nanda, R.; Tretiakova, M. S.; Olopade, O. I.; Moore, D. T.; Perou, C. M. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma. Mod Pathol 2006, 19, 264-271.
13. Nguyen, P. L.; Taghian, A. G.; Katz, M. S.; Niemierko, A.; Abi Raad, R. F.; Boon, W. L.; Bellon, J. R.; Wong, J. S.; Smith, B. L.; Harris, J. R. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26, 2373-2378.
14. Harvey, J. M.; Clark, G. M.; Osborne, K.; Allred, D. C. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17, 1474-1481.
15. Wolff, A. C.; Hammond, M. E.; Schartz, J. N.; Hagerty, K. L.; Allred, D. C.; Cote, R. J.; Dowsett, M.; Fitzgibbons, P. L.; Hanna, W. M.; Langer, A.; McShane, L. M.; Paik, S.; Pegram, M. D.; Perez, E. A.; Press, M. F.; Rhodes, A.; Sturgeon, C.; Taube, S. E.; Tubbs, R.; Vance, G. H.; van de Vijver, M.; Wheeler, T. M.; Hayes, D. F. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25, 118-145.
16. Tang, P.; Wang, J.. Bourne, P. Molecular classifications of breast carcinomas with similar terminology and different definitions: are they the same? Hum Pathol 2008, 39, 506-513.
17. Lyman, G. H.; Cosler, L. E.; Kuderer, N. M.; Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. Cancer 2007, 109, 1011-1018.
18. Gianni, L.; Zambetti, M.; Clark, K.; Baker, J.; Cronin, M.; Wu, J.; Mariani, G.; Rodriguez, J.; Carcangiu, M.; Watson, D.; Valagussa, P.; Rouzier, R.; Symmans, W. F.; Ross, J. S.; Hortobagyi, G. N.; Pusztai, L.; Shak, S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23, 7265-7277.
19. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F. L.; Watson, D.; Bryant, J.; Costantino, J. P.; Geyer, C. E. Jr.; Wickerham, D. L.; Wolmark, N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006, 24, 3726-3734.
20. Habel, L. A.; Shak, S.; Jacobs, M. K.; Capra, A.; Alexander, C.; Pho, M.; Baker, J.; Walker, M.; Watson, D.; Hackett, J.; Blick, N. T.; Greenberg, D.; Fehrenbacher, L.; Langholz, B.; Quesenberry, C. P. A population-based study of tumor gene expression and risk of breast cancer death among lymph node negative patients. Breast Cancer Res 2006, 8 [3]: R25.
21. Mina, L.; Soule, S. E.; Badve, S.; Baehner, F. L.; Baker, J.; Cronin, M.; Watson, D.; Liu, M. L.; Sledge, G. W. Jr.; Shak, S.; Miller, K. D. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007, 103, 197-208.
22. Cronin, M.; Sangli, C.; Liu, M. L.; Pho, M.; Dutta, D.; Nguyen, A.; Jeong, J.; Wu, J.; Langone, K. C.; Watson, D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor positive breast cancer. Clin Chem 2007, 53, 1084-1091.
23. Flanagan, M. B.; Dabbs, D. J.; Brufsky, A. M.; Beriwal, S.; Bhargava, R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008, 21, 1255-1261.
24. Wolf, I.; Ben-Baruch, N.; Shapira-Frommer, R.; Rizel, S.; Goldberg, H.; Yaal-Hahoshen, N.; Klein, B.; Geffen, D. B.; Kaufman, B. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 2008, 112, 731-736.
25. Asad, J.; Jacobson, A. F.; Estabrook, A.; Smith, S. R.; Boolbol, S. K.; Feldman, S. M.; Osborne, M. P.; Boachie-Adjei, K.; Twardzik, W.; Tartter, P. I. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008, 196, 527-529.
26. Rakha, E. A.; El-Sayed, M. E.; Green, A. R.; Paish, E. C.; Powe, D. G.; Gee, J.; Nicholson, R. I.; Lee, A. H.; Robertson, J. F.; Ellis, I. O. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25, 4772-4778.
27. Arpino, G.; Weiss, H.; Lee, A. V.; Schiff, R.; De Placido, S.; Osborne, C. K.; Elledge, R. M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97, 1254-1261. (Pubitemid 41535366)
28. Ponzone, R.; Montemurro, F.; Maggiorotto, F.; Robba, C.; Gregori, D.; Jacomuzzi, M. E.; Kubatzki, F.; Marenco, D.; Dominguez, A.; Biglia, N.; Sismondi, P. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 2006, 17, 1631-1636.
29. Kim, H. J.; Cui, X.; Hilsenbeck, S. G.; Lee, A. V. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006, 12, 1013s-1018s.
30. Bardou, V. J.; Arpino, G.; Elledge, R. M.; Osborne, C. K.; Clark, G. M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21, 1973-1979.
31. Loi, S.; Haibe-Kains, B.; Desmedt, C.; Lallemand, F.; Tutt, A. M.; Gillet, C.; Ellis, P.; Harris, A.; Bergh, J.; Foekens, J. A.; Klijn, J. G.; Larsimont, D.; Buyse, M.; Bontempi, G.; Delorenzi, M.; Piccart, M. J.; Sotiriou, C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25, 1239-1246.
32. Dunnwald, L. K.; Rossing, M. A.; Li, C. I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9: R6.
33. Wei, B.; Wang, J.; Bourne, P.; Yang, Q.; Hicks, D.; Bu, H.; Tang, P. Bone metastasis is strongly associated with estrogen receptorpositive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008, 39, 1809-1815.
34. Cui, X.; Schiff, R.; Arpino, G.; Osborne, C. K.; Lee, A. V. Biology of progesterone receptor loss in breast cancer and its implication for endocrine therapy. J Clin Oncol 2005, 23, 7721-7735.
35. Dowsett, M.. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003, 82, S7.
36. Osborne, C. K.; Shou, J.; Masserweh, S.; Schiff, R. Crosstalk between estrogen receptor and growth factor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11, 865-876.
37. Chhieng, D. C.; Frost, A. R.; Niwas, S.; Weiss, H.; Grizzle, W. E.; Beeken, S. Intratumor heterogeneity of biomarker expression in breast carcinomas Biotech Histochem 2004, 79, 25-36.
38. Graham, A. D.; Faratian, D.; Rae, F.; Thomas, J. S. Tissue microarray technology in the routine assessment of HER-2 status invasive breast cancer: a prospective study of the use of immunohistochemical and fluorescence in situ hybridization. Histopathology 2008, 52, 847-855.
39. Hatem, J.; Lin, Y.; Wang, J. M.; Hicks, D. G.; Tang, P. Tissue microarray (TMA)-based IHC study can significantly underestimate the expression of HER2. Mod Pathol 2009, 22 (Suppl.), 46A.